Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison, Tim W.; Chanez, Pascal; Menzella, Francescoet al.
[en] BACKGROUND: ANDHI was done to assess the efficacy of benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms. METHODS: This phase 3b, randomised, double-blind, parallel-group, placebo-controlled ANDHI study was completed in adults (aged 18-75 years) with severe eosinophilic asthma with at least 2 exacerbations in the previous year, despite high-dose inhaled corticosteroid plus additional controllers, screening blood eosinophil counts of at least 150 cells per μL, and an Asthma Control Questionnaire 6 (ACQ-6) score of 1·5 or more. Patients who met eligibility criteria were randomly assigned (2:1; stratified by previous exacerbation count [two, or three or more], maintenance oral corticosteroid use, and region), using an integrated web-based response system, to receive benralizumab at 30 mg every 8 weeks (first three doses given 4 weeks apart) or matched placebo for 24 weeks. Primary efficacy measure was annualised asthma exacerbation rate, with rate ratio (RR) calculated over the approximate 24-week follow-up. Secondary efficacy measures included change from baseline to end of treatment (week 24) in St George's Respiratory Questionnaire (SGRQ) total score (key secondary endpoint), FEV(1), peak expiratory flow (PEF), ACQ-6, Predominant Symptom and Impairment Assessment (PSIA), Clinician Global Impression of Change (CGI-C), Patient Global Impression of Change (PGI-C), and Sino-Nasal Outcome Test-22 (SNOT-22). All efficacy analyses, except for SNOT-22, were summarised and analysed using the full analysis set on an intention-to-treat population (all randomly assigned patients receiving investigational product, regardless of protocol adherence or continued participation in the study). SNOT-22 was summarised for the subgroup of patients with physician-diagnosed nasal polyposis with informed consent. This study is registered with ClinicalTrials.gov, NCT03170271. FINDINGS: Between July 7, 2017, and Sept 25, 2019, 656 patients received benralizumab (n=427) or placebo (n=229). Baseline characteristics were consistent with severe eosinophilic asthma. Benralizumab significantly reduced exacerbation risk by 49% compared with placebo (RR estimate 0·51, 95% CI 0·39-0·65; p≤0·0001) over the 24-week treatment period and provided clinically meaningful and statistically significant improvement from baseline to week 24 in SGRQ total score versus placebo (least squares mean change from baseline -8·11 (95% CI -11·41 to -4·82; p≤0·0001), with similar differences at earlier timepoints. Benralizumab improved FEV(1), PEF, ACQ-6, CGI-C, PGI-C, PSIA, and SNOT-22 at week 24 versus placebo, with differences observed early (within weeks 1 to 4). Adverse events were reported for 271 (63%) of 427 patients on benralizumab versus 143 (62%) of 229 patients on placebo. The most commonly reported adverse events for the 427 patients receiving benralizumab (frequency >5%) were nasopharyngitis (30 [7%]), headache (37 [9%]), sinusitis (28 [7%]), bronchitis (22 [5%]), and pyrexia (26 [6%]). Fewer serious adverse events were reported for benralizumab (23 [5%]) versus placebo (25 [11%]), and the only common serious adverse event (experienced by >1% of patients) was worsening of asthma, which was reported for nine (2%) patients in the benralizumab group and nine (4%) patients in the placebo group. INTERPRETATION: Our results extend the efficacy profile of benralizumab for patients with severe eosinophilic asthma, showing early clinical benefits in patient-reported outcomes, HRQOL, lung function, and nasal polyposis symptoms. FUNDING: AstraZeneca.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Harrison, Tim W.
Chanez, Pascal
Menzella, Francesco
Canonica, Giorgio Walter
Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie
Cosio, Borja G.
Lugogo, Njira L.
Mohan, Arjun
Burden, Annie
McDermott, Lawrence
Garcia Gil, Esther
Zangrilli, James G.
Language :
English
Title :
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
WHO. Asthma. https://www.who.int/news-room/q-a-detail/asthma, 2019. (Accessed 11 May 2020)
To, T, Stanojevic, S, Moores, G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health, 12, 2012, 204.
Chung, KF, Wenzel, SE, Brozek, JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43 (2014), 343–373.
Papi, A, Brightling, C, Pedersen, SE, Reddel, HK, Asthma. Lancet 391 (2018), 783–800.
Busse, WW, Biological treatments for severe asthma: a major advance in asthma care. Allergol Int 68 (2019), 158–166.
Colas, L, Hassoun, D, Magnan, A, Needs for systems approaches to better treat individuals with severe asthma: predicting phenotypes and responses to treatments. Front Med, 7, 2020, 98.
Kolbeck, R, Kozhich, A, Koike, M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 125 (2010), 1344–1353.
Pham, TH, Damera, G, Newbold, P, Ranade, K, Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med 111 (2016), 21–29.
Busse, WW, Katial, R, Gossage, D, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 125 (2010), 1237–1244.
Laviolette, M, Gossage, DL, Gauvreau, G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 132 (2013), 1086–1096.
Bleecker, ER, FitzGerald, JM, Chanez, P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388 (2016), 2115–2127.
FitzGerald, JM, Bleecker, ER, Nair, P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388 (2016), 2128–2141.
Nair, P, Wenzel, S, Rabe, KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 376 (2017), 2448–2458.
FitzGerald, JM, Bleecker, ER, Menzies-Gow, A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med 6 (2018), 51–64.
Goldman, M, Hirsch, I, Zangrilli, JG, Newbold, P, Xu, X, The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the phase III SIROCCO and CALIMA studies. Curr Med Res Opin 33 (2017), 1605–1613.
Humbert, M, Increasing confidence in the therapeutic relevance of eosinophils in severe asthma. Lancet Respir Med 6 (2018), 7–8.
Bleecker, ER, Wechsler, ME, FitzGerald, JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J, 52, 2018, 1800936.
Busse, WW, Bleecker, ER, FitzGerald, JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med 7 (2019), 46–59.
O'Quinn, S, Xu, X, Hirsch, I, Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma. J Asthma Allergy 12 (2019), 21–33.
Håkansson, K, Bachert, C, Konge, L, et al. Airway inflammation in chronic rhinosinusitis with nasal polyps and asthma: the United Airways concept further supported. PLoS One, 10, 2015, e0127228.
Settipane, GA, Chafee, FH, Nasal polyps in asthma and rhinitis. A review of 6,037 patients. J Allergy Clin Immunol 59 (1977), 17–21.
Dávila, I, Rondón, C, Navarro, A, et al. Aeroallergen sensitization influences quality of life and comorbidities in patients with nasal polyposis. Am J Rhinol Allergy 26 (2012), e126–e131.
Bilodeau, L, Boulay, ME, Prince, P, Boisvert, P, Boulet, LP, Comparative clinical and airway inflammatory features of asthmatics with or without polyps. Rhinology 48 (2010), 420–425.
Hall, R, Trennery, C, Chan, R, et al. Understanding the patient experience of severe, recurrent, bilateral nasal polyps: a qualitative interview study in the United States and Germany. Value Health 23 (2020), 632–641.
Fokkens, WJ, Lund, V, Bachert, C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 74 (2019), 2312–2319.
Sahlstrand-Johnson, P, Ohlsson, B, Von Buchwald, C, Jannert, M, Ahlner-Elmqvist, M, A multi-centre study on quality of life and absenteeism in patients with CRS referred for endoscopic surgery. Rhinology 49 (2011), 420–428.
Van Zele, T, Claeys, S, Gevaert, P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 61 (2006), 1280–1289.
Fokkens, WJ, Lund, VJ, Mullol, J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 50 (2012), 1–12.
Langdon, C, Mullol, J, Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy 9 (2016), 45–53.
Schlosser, RJ, Smith, TL, Mace, J, Soler, ZM, Asthma quality of life and control after sinus surgery in patients with chronic rhinosinusitis. Allergy 72 (2017), 483–491.
Phillips, KM, Hoehle, LP, Bergmark, RW, et al. Chronic rhinosinusitis severity is associated with need for asthma-related systemic corticosteroids. Rhinology 55 (2017), 211–217.
Phillips, KM, Bergmark, RW, Hoehle, LP, Caradonna, DS, Gray, ST, Sedaghat, AR, Chronic rhinosinusitis exacerbations are differentially associated with lost productivity based on asthma status. Rhinology 56 (2018), 323–329.
Bachert, C, Hellings, PW, Mullol, J, et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy 75 (2020), 148–157.
Neubauer, PD, Schwam, ZG, Manes, RP, Comparison of intranasal fluticasone spray, budesonide atomizer, and budesonide respules in patients with chronic rhinosinusitis with polyposis after endoscopic sinus surgery. Int Forum Allergy Rhinol 6 (2016), 233–237.
Li, N, Peters, AT, Chronic rhinosinusitis management beyond intranasal steroids and saline solution irrigations. Allergy Asthma Proc 36 (2015), 339–343.
van der Veen, J, Seys, SF, Timmermans, M, et al. Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre. Allergy 72 (2017), 282–290.
Fokkens, WJ, Lund, VJ, Hopkins, C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58:suppl S29 (2020), 1–464.
Brown, WC, Senior, B, A critical look at the efficacy and costs of biologic therapy for chronic rhinosinusitis with nasal polyposis. Curr Allergy Asthma Rep, 20, 2020, 16.
Bachert, C, Han, JK, Desrosiers, M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394 (2019), 1638–1650.
Bachert, C, Hellings, PW, Mullol, J, et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy 75 (2020), 148–157.
Biospace. Xolair (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies. https://www.biospace.com/article/releases/xolairomalizumab-significantly-reduced-nasal-polyps-and-congestion-symptoms-inadults-with-chronic-rhinosinusitis-with-nasal-polyps-in-two-phase-iii-studies. (Accessed 12 May 2020)
Yilmaz, I, Türk, M, Nazik Bahçecioğlu, S, Tutar, N, Gülmez, I, Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study. Turk J Med Sci 50 (2020), 433–441.
Pelaia, C, Busceti, MT, Vatrella, A, et al. Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma. SAGE Open Med Case Rep, 8, 2020, 2050313X20906963.
Tsurumaki, H, Matsuyama, T, Ezawa, K, et al. Rapid effect of benralizumab for hypereosinophilia in a case of severe asthma with eosinophilic chronic rhinosinusitis. Medicina, 55, 2019, E336.
Minami, D, Kayatani, H, Sato, K, Fujiwara, K, Shibayama, T, Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab. Respirol Case Rep, 7, 2018, e00388.
Jones, PW, Quirk, FH, Baveystock, CM, The St George's respiratory questionnaire. Respir Med 85:suppl B (1991), 25–31.
Miller, MR, Crapo, R, Hankinson, J, et al. General considerations for lung function testing. Eur Respir J 26 (2005), 153–161.
Juniper, EF, Svensson, K, Mörk, AC, Ståhl, E, Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 99 (2005), 553–558.
Bel, EH, Wenzel, SE, Thompson, PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371 (2014), 1189–1197.
Ortega, HG, Liu, MC, Pavord, ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 (2014), 1198–1207.
Park, HS, Lee, SH, Lee, SY, et al. Efficacy and safety of benralizumab for Korean patients with severe, uncontrolled eosinophilic asthma. Allergy Asthma Immunol Res 11 (2019), 508–518.
Panettieri, RA Jr, Welte, T, Shenoy, KV, et al. Onset of effect, changes in airflow obstruction and lung volume, and health-related quality of life improvements with benralizumab for patients with severe eosinophilic asthma: phase IIIb randomized, controlled trial (SOLANA). J Asthma Allergy 13 (2020), 115–126.
Global Initiative for Asthma. Global strategy for asthma management and prevention. www.ginasthma.org, 2020. (Accessed 16 July 2020)
Herman, E, Beavers, S, Hamlin, B, Thaker, K, Is it time for a patient-centered quality measure of asthma control?. J Allergy Clin Immunol Pract 7 (2019), 1771–1777.
American Academy of Allergy Asthma & Immunology. Biologics for the management of severe asthma. https://www.aaaai.org/conditions-and-treatments/library/asthma-library/biologics-asthma, 2019. (Accessed 13 July 2020)
de Groot, JC, Ten Brinke, A, Bel, EH, Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res 1 (2015), 00024–02015.
Kartush, AG, Schumacher, JK, Shah, R, Patadia, MO, Biologic agents for the treatment of chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy 33 (2019), 203–211.
Ren, L, Zhang, N, Zhang, L, Bachert, C, Biologics for the treatment of chronic rhinosinusitis with nasal polyps—state of the art. World Allergy Organ J, 12, 2019, 100050.